PharmPlanNet Contract Research GmbH
Mönchengladbach, 41061, Germany
NCT Number: NCT00189943
The purpose of this study is to collect information on the safety, tolerability and immunogenicity of an investigational smallpox vaccine at different doses and using different routes of administration in vaccinia-naive and vaccinated healthy volunteers
Looking for future studies?
Notify Me20 year–55 year
Male
Interventional
Phase 1
Mönchengladbach, 41061, Germany
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Bavarian Nordic
Industry
Phase I Study on Safety, Tolerability and Immunogenicity of the MVA-BN Vaccine Administered to Healthy Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00437021
DNA Virus Infections, Infections
Iowa City, Iowa, United States
View Trial DetailsNCT05995275
Animal Diseases, DNA Virus Infections
Bradford, United Kingdom
View Trial DetailsNCT00879762
DNA Virus Infections, Infections
Iowa City, Iowa, United States
View Trial DetailsNCT05935917
DNA Virus Infections, Infections
Overland Park, Kansas, United States
View Trial Details